Penumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company's peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: PEN
- Previous Close: $78.85
- 50 Day Moving Average: $73.20
- 200 Day Moving Average: $70.16
- 52-Week Range: $41.35 - $79.90
- Trailing P/E Ratio: 3178.00
- Foreward P/E Ratio: -1,958.75
- P/E Growth: -16.98
- Market Cap: $2.51B
- Outstanding Shares: 31,643,000
- Beta: 0.15
- Net Margins: 0.61%
- Return on Equity: 0.61%
- Return on Assets: 0.53%
Companies Related to Penumbra:
- Current Ratio: 7.16%
- Quick Ratio: 5.28%
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
Where is Penumbra's stock going? Where will Penumbra's stock price be in 2017?
3 brokers have issued 12-month price objectives for Penumbra's stock. Their predictions range from $67.00 to $86.00. On average, they anticipate Penumbra's share price to reach $76.50 in the next twelve months.
When will Penumbra announce their earnings?
Penumbra is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Penumbra stock?
Penumbra's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Federated Investors Inc. PA (1.64%), State Street Corp (1.49%), Champlain Investment Partners LLC (0.98%), Franklin Resources Inc. (0.64%) and Artisan Partners Limited Partnership (0.49%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Daniel Donen Davis, Don W Kassing, James Robert Pray, Lynn Rothman, Robert D Evans and Sridhar Kosaraju.
Who sold Penumbra stock? Who is selling Penumbra stock?
Penumbra's stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, Highland Capital Management LP, AQR Capital Management LLC, Mission Wealth Management LLC, Nicholas Investment Partners LP and Franklin Resources Inc.. Company insiders that have sold Penumbra stock in the last year include Adam Elsesser, Arani Bose, Daniel Donen Davis, Don W Kassing, James Robert Pray, Lynn Rothman, Robert D Evans and Sridhar Kosaraju.
Who bought Penumbra stock? Who is buying Penumbra stock?
Penumbra's stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Federated Investors Inc. PA, Artisan Partners Limited Partnership, FMR LLC, Russell Investments Group Ltd., Loomis Sayles & Co. L P, State Street Corp and Advisory Research Inc..
How do I buy Penumbra stock?
Shares of Penumbra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Penumbra stock cost?
One share of Penumbra stock can currently be purchased for approximately $78.35.